COCIR fully supports the European Joint Action EUnetHTA which aims to develop a European approach to Health Technology Assessment (HTA). COCIR believes that HTA, if applied properly, will show the benefits of healthcare technology and facilitate faster adoption of safe and efficient innovative medical technology.
Publishing a position paper ‘Measuring the value of Medical Technology, Devices and Healthcare IT: The Role of Health Technology Assessment (HTA)’ today, COCIR sets out a number of industry expectations on how reliable, transparent and consistent HTA processes should be organised.
COCIR believes that HTA methodologies will allow COCIR members demonstrate the value of safe and efficient innovative technologies as a means to deliver high-quality health care services rather than as generating additional cost burden. COCIR hopes that these recommendations will help shape the future of HTA for our technologies and contribute to speeding up market access and enabling a better uptake.
Nicole Denjoy, COCIR Secretary General said “If HTAs are applied consistently at EU level, the argument for sustainable investment in healthcare technology will be more compelling than ever. This will be of benefit not just to citizens across Europe but, in line with the EU’s new Innovation Union strategy, it could also support innovative employment and wealth creation in Europe. By helping to remove bottlenecks to investment in innovation, COCIR believes that HTAs will be a useful tool to help trigger industry innovation in healthcare and healthcare IT.”
Sign up feature for press releases
For press questions please contact:
COCIR Communications Advisor
00 32 (0) 496 116198